Cited by 274Diabetes Treatment and ManagementCardiovascular Function and Risk FactorsHeart Failure Treatment and Management

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

Nikolaidis, Lazaros A., Elahi, Dariush, Shen, You-Tang, Shannon, Richard P.·2005·American Journal of Physiology-Heart and Circulatory Physiology

DOI 10.1152/ajpheart.00347.2005

Open this paper in CoChat — free account

Abstract

We have shown previously that the glucagon-like peptide-1 (GLP-1)-(7–36) amide increases myocardial glucose uptake and improves left ventricular (LV) and systemic hemodynamics in both conscious dogs with pacing-induced dilated cardiomyopathy (DCM) and humans with LV systolic dysfunction after acute myocardial infarction. However, GLP-1-(7–36) is rapidly degraded in the plasma to GLP-1-(9–36) by dipeptidyl peptidase IV (DPP IV), raising the issue of which peptide is the active moiety. By way of methodology, we compared the efficacy of a 48-h continuous intravenous infusion of GLP-1-(7–36) (1.5 pmol·kg−1·min−1) to GLP-1-(9–36) (1.5 pmol·kg−1·min−1) in 28 conscious, chronically instrumented dogs with pacing-induced DCM by measuring LV function and transmyocardial substrate uptake under basal and insulin-stimulated conditions using hyperinsulinemic-euglycemic clamps. As a result, dogs with DCM demonstrated myocardial insulin resistance under basal and insulin-stimulated conditions. Both GLP-1-(7–36) and GLP-1-(9–36) significantly reduced ( P < 0.01) LV end-diastolic pressure [GLP-1-(7–36), 28 ± 1 to 15 ± 2 mmHg; GLP-1-(9–36), 29 ± 2 to 16 ± 1 mmHg] and significantly increased ( P < 0.01) the first derivative of LV pressure [GLP-1-(7–36), 1,315 ± 81 to 2,195 ± 102 mmHg/s; GLP-1-(9–36), 1,336 ± 77 to 2,208 ± 68 mmHg] and cardiac output [GLP-1-(7–36), 1.5 ± 0.1 to 1.9 ± 0.1 l/min; GLP-1-(9–36), 2.0 ± 0.1 to 2.4 ± 0.05 l/min], whereas an equivolume infusion of saline had no effect. Both peptides increased myocardial glucose uptake but without a significant increase in plasma insulin. During the GLP-1-(9–36) infusion, negligible active (NH 2-terminal) peptide was measured in the plasma. In conclusion, in DCM, GLP-1-(9–36) mimics the effects of GLP-1-(7–36) in stimulating myocardial glucose uptake and improving LV and systemic hemodynamics through insulinomimetic as opposed to insulinotropic effects. These data suggest that GLP-1-(9–36) amide is an active peptide.

Integrity signals

Registry

Crossref · 10.1152/ajpheart.00347.2005

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Self-citation
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 644
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/endo.137.7.8770921 · Cited by 622
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 3×
“There is a growing body of evidence supporting the efficacy of GLP-1-(7–36) amide as a potent stimulus to insulin release (insulinotropic) in Type 2 diabetes mellitus (10, 15, 19).”
Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy
Nikolaidis, L., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C. J., Shen, Y.-T., & Shannon, R. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 546
Self-citation
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J., Lopez, M. E., Hollenberg, A., Baggio, L., Saper, C., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15595 · Cited by 544
Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 537
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
A Recombinant Human Glucagon-Like Peptide (GLP)-1–Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor–Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 389

Show all 27 references

Sorted by citations

Items 101–200 of 272

Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus
Moberly, S. P., Mather, K. J., Berwick, Z. C., Owen, M. K., Goodwill, A. G., Casalini, E. D., Hutchins, G. D., Green, M. A., Ng, Y., Considine, R. V., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0365-x · Cited by 51
Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome
Vergès, B. L., Avignon, A., Bonnet, F., Catargi, B., Cattan, S., Cosson, E., Ducrocq, G., Elbaz, M., Fredenrich, A., Gourdy, P., et al. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.003 · Cited by 51
Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.525 · Cited by 50
Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice
Porter, D., Faivre, É., Flatt, P. R., Hölscher, C., & Gault, V. A. (2012) · Peptides · doi:10.1016/j.peptides.2012.03.014 · Cited by 51
Incretin-based therapies: mimetics versus protease inhibitors
Brubaker, P. L. (2007) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.06.005 · Cited by 49
In patients with ST-segment elevation myocardial infarction with cardiogenic shock treated with percutaneous coronary intervention, admission glucose level is a strong independent predictor for 1-year mortality in patients without a prior diagnosis of diabetes
Vis, M. M., Sjauw, K. D., van der Schaaf, R. J., Baan, J., Koch, K. T., DeVries, J. H., Tijssen, J. G. P., de Winter, R. J., Piek, J. J., & Henriques, J. P. S. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.028 · Cited by 49
Glucagon‐like peptide‐1(9‐36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet‐induced obese mice
Tomás, E., Wood, J. A., Stanojevic, V., & Habener, J. F. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01316.x · Cited by 48
Unique roles of glucagon and glucagon-like peptides: Parallels in understanding the functions of adipokinetic hormones in stress responses in insects
Bednářová, A., Kodrı́k, D., & Krishnan, N. (2012) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2012.10.012 · Cited by 48
Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats
Lim, S. K., Lee, G. Y., Park, H. S., Lee, D., Jung, O. T., Min, K. K., Kim, Y., Jun, H., Chul, J. H., & Park, K. S. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw213 · Cited by 48
Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
Li, J., Zheng, J., Wang, S., Lau, H., Fathi, A., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00015 · Cited by 48
Glucagon-like Peptide-1 (GLP-1) and Protective Effects in Cardiovascular Disease: A New Therapeutic Approach for Myocardial Protection
Zhao, T. C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-90 · Cited by 45
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Lotfy, M. A., Singh, J., Kalász, H., Tekes, K., & Adeghate, E. A. (2011) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501105010082 · Cited by 44
GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats
Ku, H.-C., Chen, W., & Su, M. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0559-9 · Cited by 43
Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study
Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1000-2 · Cited by 43
Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKCε/ERK1/2 pathway
Zhu, Q., Luo, Y., Wen, Y., Wang, D., Li, J., & Fan, Z. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.01.049 · Cited by 44
GLP-1-derived nonapeptide GLP-1(28–36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice
Ip, W., Shao, W., Chiang, Y.-T. A., & Jin, T. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00376.2013 · Cited by 43
Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts
Du, J., Zhang, L., Wang, Z., Yano, N., Zhao, Y., Lei, W., Dubielecka, P. M., Liu, P. Y., Zhuang, S., Qin, G., et al. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00194.2015 · Cited by 44
The evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 42
GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction
Nguyễn, T. D., Shingu, Y., Amorim, P., Schenkl, C., Schwarzer, M., & Doenst, T. (2018) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-018-9795-z · Cited by 41
GLP‐1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes
Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13045 · Cited by 40
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 42
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 41
Mining incretin hormone pathways for novel therapies
Wideman, R. D., & Kieffer, T. J. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.02.005 · Cited by 39
Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function
Halbirk, M., Nørrelund, H., Møller, N., Schmitz, O., Gøtzsche, L. B.-H., Nielsen, R. R., Nielsen‐Kudsk, J. E., Nielsen, S. S., Nielsen, T. T., Eiskjær, H., et al. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00475.2010 · Cited by 40
Congestive Heart Failure and Diabetes Mellitus: Balancing Glycemic Control with Heart Failure Improvement
Nasir, S., & Aguilar, D. A. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.031 · Cited by 39
Incretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products
Guglielmi, V., & Sbraccia, P. (2016) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-016-0352-y · Cited by 37
Incretin-based therapies and cardiovascular risk
Mannucci, E., & Dicembrini, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.678940 · Cited by 35
Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3
Tsutsumi, Y. M., Tsutsumi, R., Hamaguchi, E., Sakai, Y., Kasai, A., Ishikawa, Y., Yokoyama, U., & Tanaka, K. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0132-9 · Cited by 35
Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Janardhan, S., & Sastry, G. N. (2014) · Current Drug Targets · doi:10.2174/1389450115666140311102638 · Cited by 35
Glucagon-Like Peptide-1
Giblett, J. P., Clarke, S. J., Dutka, D. P., & Hoole, S. P. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.011 · Cited by 36
In Vitro Metabolism of the Glucagon-Like Peptide-1 (GLP-1)–Derived Metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human Hepatocytes
Sharma, R., McDonald, T. S., Eng, H. F., Limberakis, C., Stevens, B. D., Patel, S., & Kalgutkar, A. S. S. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054254 · Cited by 34
Metabolically-inactive glucagon-like peptide-1(9–36)amide confers selective protective actions against post-myocardial infarction remodelling
Robinson, E., Tate, M., Lockhart, S. M., McPeake, C., O’Neill, K. M., Edgar, K. S., Calderwood, D., Green, B. D., McDermott, B. J., & Grieve, D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0386-5 · Cited by 35
GLP-1 Therapy
Hausenloy, D. J., & Yellon, D. M. (2008) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.810887 · Cited by 35
Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial
Besch, G., Perrotti, A., du Mont, L. S., Puyraveau, M., Ben-Said, X., Baltres, M., Barrucand, B., Flicoteaux, G., Vettoretti, L., Samain, E., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0784-y · Cited by 33
Selective targeting of glucagon‐like peptide‐1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
Glucagon and a glucagon‐GLP‐1 dual‐agonist increases cardiac performance with different metabolic effects in insulin‐resistant hearts
Axelsen, L. N., Keung, W., Pedersen, H. D., Meier, E., Riber, D., Kjølbye, A. L., Petersen, J., Proctor, S. D., Holstein‐Rathlou, N., & Lopaschuk, G. D. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01714.x · Cited by 34
Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies
Addison, D., & Aguilar, D. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0153-0 · Cited by 32
A Meta-Analysis of the Therapeutic Effects of Glucagon-Like Peptide-1 Agonist in Heart Failure
Munaf, M., Pellicori, P., Allgar, V. L., & Wong, K. (2012) · International Journal of Peptides · doi:10.1155/2012/249827 · Cited by 31
GLP-1(32–36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs
Elahi, D., Angeli, F. S., Vakilipour, A., Carlson, O. D., Tomás, E., Egan, J. M., Habener, J. F., & Shannon, R. P. (2014) · Peptides · doi:10.1016/j.peptides.2014.06.004 · Cited by 29
Self-citation
Possible involvement of GLP‐1(9–36) in the regional haemodynamic effects of GLP‐1(7–36) in conscious rats
Gardiner, S., March, J., Kemp, P. A., Bennett, T. M., & Dj, B. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00867.x · Cited by 28
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 27
Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism
Batran, R. A., Almutairi, M. G., & Ussher, J. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.005 · Cited by 28
Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27
“These benefits are also present in the presence of active metabolite of GLP-1 [56].”
Incretin-based therapies: can we achieve glycemic control and cardioprotection?
Angeli, F. S., & Shannon, R. P. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0195 · Cited by 27
Self-citation
A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
Chen, L., Zhang, J., Sun, Y., Zhao, Y., Liu, X., Fang, Z., Feng, L., He, B., Zou, Q., & Tracey, G. J. (2023) · Nature Communications · doi:10.1038/s41467-023-36946-7 · Cited by 27
Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
Nozue, T., Yamada, M., Tsunoda, T., Katoh, H., Ito, S., Iwaki, T., & Michishita, I. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0734-5 · Cited by 25
Glucagon-Like Peptide 1—A Cardiologic Dimension
Treiman, M., Elvekjær, M., Engstrøm, T., & Jensen, J. S. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.02.012 · Cited by 27
The pleiotropic cardiovascular effects of dipeptidyl peptidase‐4 inhibitors
Avogaro, A., & Fadini, G. P. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13611 · Cited by 28
Cardiovascular Effects of Incretin-Based Therapies
White, W. B., & Baker, W. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-050214-013431 · Cited by 26
Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
Kang, S. M., & Park, J. H. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211051698 · Cited by 31
The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential
Mustafa, O. G., & Whyte, M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3191 · Cited by 27
Exendin-4 exhibits cardioprotective effects against high glucose-induced mitochondrial abnormalities: Potential role of GLP-1 receptor and mTOR signaling
Parichatikanond, W., Pandey, S., & Mangmool, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116552 · Cited by 24
Cardiovascular Effects of Incretins in Diabetes
Advani, A., Bugyei‐Twum, A., & Connelly, K. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.06.010 · Cited by 25
Incretin hormones as immunomodulators of atherosclerosis
Alonso, N., Julián, M. T., Puig‐Domingo, M., & Vives‐Pi, M. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00112 · Cited by 24
The role of incretins in cardiovascular control
Mafong, D. D., & Henry, R. R. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0005-x · Cited by 23
Insulin Resistance and Skeletal Muscle Vasculature: Significance, Assessment and Therapeutic Modulators
Manrique, C. M., & Sowers, J. R. (2014) · Cardiorenal Medicine · doi:10.1159/000368423 · Cited by 23
Impact of glucagon‐like peptide‐1 on endothelial function
Sjöholm, Å. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01074.x · Cited by 22
Effects of Glucagon-Like Peptide-1 and Long-Acting Analogues on??Cardiovascular and Metabolic Function
Saraceni, C., & Broderick, T. L. (2007) · Drugs in R&D · doi:10.2165/00126839-200708030-00002 · Cited by 22
Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow
Moberly, S. P., Berwick, Z. C., Owen, M. K., Svendsen, M., Mather, K. J., & Tune, J. D. (2012) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011288 · Cited by 22
Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome
Day, S. M., Yang, W., Wang, X., Stern, J. E., Zhou, X., Macauley, S. L., & Ma, T. (2019) · eNeuro · doi:10.1523/eneuro.0031-19.2019 · Cited by 21
Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway
Arad, M., Waldman, M., Abraham, N. G., & Hochhauser, E. (2020) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2020.106454 · Cited by 20
Novel Angiogenesis Role of GLP-1(32–36) to Rescue Diabetic Ischemic Lower Limbs via GLP-1R–Dependent Glycolysis in Mice
Zhang, Y., Wang, S., Zhou, Q., Hu, Y., Xie, Y., Fang, W., Yang, C., Wang, Z., Ye, S., Wang, X., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320714 · Cited by 19
DPP4 Deficiency Preserved Cardiac Function in Abdominal Aortic Banding Rats
Ku, H.-C., & Su, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085634 · Cited by 19
Potential cardiovascular effects of incretin-based therapies
Deacon, C. F., & Marx, N. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.5 · Cited by 19
Glucagon-like peptide-1 (7–36) but not (9–36) augments cardiac output during myocardial ischemia via a Frank–Starling mechanism
Goodwill, A. G., Tune, J. D., Noblet, J. N., Conteh, A. M., Sassoon, D., Casalini, E. D., & Mather, K. J. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0426-9 · Cited by 18
Cardiovascular and hemodynamic effects of glucagon-like peptide-1
Goodwill, A. G., Mather, K. J., Conteh, A. M., Sassoon, D., Noblet, J. N., & Tune, J. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9290-z · Cited by 17
Glucagon-like peptide-1 receptor antagonism impairs basal exercise capacity and vascular adaptation to aerobic exercise training in rats
Scalzo, R. L., Knaub, L. A., Hull, S., Keller, A. C., Hunter, K. S., Walker, L. A., & Reusch, J. E. B. (2018) · Physiological Reports · doi:10.14814/phy2.13754 · Cited by 17
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
The incretin system and cardiometabolic disease
Szmitko, P. E., Leiter, L. A., & Verma, S. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70010-6 · Cited by 17
A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite
Albrechtsen, N. J. W., Asmar, A., Jensen, F. H., Toräng, S., Simonsen, L., Kuhre, R. E., Asmar, M., Veedfald, S., Plamboeck, A., Knop, F. K., et al. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00005.2017 · Cited by 15
Glucagon‐like peptide‐1 cleavage product GLP‐1 (9‐36) amide enhances hippocampal long‐term synaptic plasticity in correlation with suppression of Kv4.2 expression and eEF2 phosphorylation
Day, S. M., Yang, W., Ewin, S. E., Zhou, X., & Ma, T. (2017) · Hippocampus · doi:10.1002/hipo.22795 · Cited by 16
Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts
Barakat, G. M., Nuwayri‐Salti, N., Kadi, L., Bitar, K. M., Al-Jaroud, W., & Bikhazi, A. B. (2011) · General Physiology and Biophysics · doi:10.4149/gpb_2011_01_34 · Cited by 15
Cardioprotective Effects of Glucagon-like Peptide-1 (9-36) Against Oxidative Injury in H9c2 Cardiomyoblasts: Potential Role of the PI3K/Akt/NOS Pathway
Nuamnaichati, N., Parichatikanond, W., & Mangmool, S. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001159 · Cited by 15
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
Hansen, J., Brock, B., Bøtker, H. E., GJEDDE, A. H., Rungby, J., & Gejl, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9286-8 · Cited by 15
Incretin Therapy and Heart Failure
Oyama, J., & Node, K. (2014) · Circulation Journal · doi:10.1253/circj.cj-13-1561 · Cited by 14
Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals
Model, J. F. A., Rocha, D. S., Fagundes, A. D. C., & Vinagre, A. S. (2022) · Veterinary and Animal Science · doi:10.1016/j.vas.2022.100245 · Cited by 15
Hormone treatments in congestive heart failure
Lei, L., & Mao, Y. (2018) · Journal of International Medical Research · doi:10.1177/0300060518761262 · Cited by 14
Pharmacotherapy of hyperglycemia
Kulasa, K. M., & Henry, R. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903196758 · Cited by 13
Treatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 13
New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?
Jayawardene, D., Ward, G. M., O'Neal, D. N., Theverkalam, G., MacIsaac, A. I., & MacIsaac, R. J. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.05.007 · Cited by 13
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 15
Non-Insulin Injectable Treatments (Glucagon-Like Peptide-1 and Its Analogs) and Cardiovascular Disease
Lebovitz, H. E., & Banerji, M. A. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0022 · Cited by 14
Glucagon-Like Peptide-1(9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes
Liberman, A., Eßer, M., Marx, N., & Burgmaier, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058445 · Cited by 13
Glucagon-Like Peptide-1 and its Cardiovascular Effects
Heo, K., Fujiwara, K., & Abe, J. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0265-9 · Cited by 13
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes
Scalzo, R. L., Rafferty, D., Schauer, I. E., Huebschmann, A. G., Cree‐Green, M., Reusch, J. E. B., & Regensteiner, J. G. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.002 · Cited by 12
The 6th Annual World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2009) · Diabetes Care · doi:10.2337/dc09-zb09 · Cited by 11
Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression.
Hamaguchi, E., Tanaka, K., Tsutsumi, R., Sakai, Y., Fukuta, K., Kasai, A., & Tsutsumi, Y. M. (2015) · PubMed · Cited by 11
Protective Role of Glucagon-Like Peptide-1 Against High-Glucose-Induced Endothelial Oxidative Damage
Guo, L., Qiao, Y., Zhang, L., & Pan, Q. (2015) · Medicine · doi:10.1097/md.0000000000002055 · Cited by 11
The role of glucagon‑like peptide 1 in glucose homeostasis and in other aspects of human physiology
Franek, E., Gajos, G., Gumprecht, J., Kretowski, A. J., Zahorska‐Markiewicz, B., & Malecki, M. T. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.829 · Cited by 11
Pre-Operative Left Ventricular Torsion, QRS Width/CRT, and Post-Mitral Surgery Outcomes in Patients With Nonischemic, Chronic, Severe Secondary Mitral Regurgitation
Notomi, Y., Isomura, T., Kanai, S., Maeda, M., Hoshino, J., Kondo, T., Fukada, Y., & Furukawa, K. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.04.006 · Cited by 9
Incretin-Related Drug Therapy in Heart Failure
Vest, A. R. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0232-6 · Cited by 9
Effects of Glucagon-like Peptide-1 in Diabetic Rat Small Resistance Arteries
Bayram, Z., Nacıtarhan, C., & Özdem, S. S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000120 · Cited by 9
DPP-IV inhibitors: Beyond glycaemic control?
Kwok, A. J., Mashar, M., Khavandi, K., & Sabir, I. N. (2013) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2013.10.002 · Cited by 9
Deciphering ventricular GLP-1 action: time for a change of heart
Ussher, J. R. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00680.2014 · Cited by 9
GLP-1 (7–36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles
Chen, M., Angeli, F. S., Shen, Y., & Shannon, R. P. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0115-x · Cited by 9
Self-citation
Péptido similar al glucagón tipo 1 y supervivencia de la célula cardiaca
Ravassa, S., Zudaire, A., & Díez, J. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.07.007 · Cited by 9
Management of type 2 diabetes in patients with heart failure
Aguilar, D. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0039-4 · Cited by 10

Authors: Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P.
Affiliations: Allegheny General Hospital (US)
ORCID: Nikolaidis, Lazaros A.
Venue: American Journal of Physiology-Heart and Circulatory Physiology
Publisher: American Physiological Society
Published: 2005-12
Volume: 289
Issue: 6
Pages: H2401-H2408
ISSN: 0363-6135 (ISSN-L)
1522-1539
DOI: 10.1152/ajpheart.00347.2005
OpenAlex: W2169976140
Cited by: 274
References: 27
Citations by year: 2025: 4 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 4 · 2020: 5 · 2019: 12 · 2018: 12 · 2017: 8 · 2016: 19 · 2015: 15 · 2014: 29 · 2013: 22 · 2012: 26
FWCI: 6.37
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Physiology-Heart and Circulatory Physiology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (7r01da010480-09, 5r01ag023125-05)
National Institute on Aging (AG-023125)
National Institute on Drug Abuse (DA 10480)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: glucagon-like peptide-1, GLP-1(7-36), dipeptidyl peptidase IV, dilated cardiomyopathy, pacing-induced cardiomyopathy, myocardial glucose uptake, myocardial insulin resistance, left ventricular function, hemodynamics, cardiac output, myocardial substrate metabolism, hyperinsulinemic-euglycemic clamp
MeSH terms: Animals, Blood Pressure, Cardiomyopathy, Dilated, Consciousness, Coronary Circulation, Dogs, Dose-Response Relationship, Drug, Glucagon-Like Peptides, Female, Glucagon, Glucose, Heart, Heart Ventricles, Male, Myocardium, Peptide Fragments, Peptides, Stroke Volume, Treatment Outcome, Ventricular Dysfunction, Left, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks